Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07769970

Restoring Independence With Stimulation-Enhanced Treatment for People With Functional Neurological Disorder

The goal of this clinical trial is to test a new treatment for adults with walking problems due to Functional Neurological Disorder (FND).

The main question the trial aims to answer is:

- Is stimulation-enhanced physical therapy an effective treatment for walking problems due to FND?

Researchers will compare the stimulation-enhanced physical therapy to gold-standard physical therapy.

Participants will:

* Complete three in-person sessions on three consecutive days * Complete follow-up assessments by video call at 7 days, 30 days and 90 days after treatment

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This clinical trial is for people who have difficulty walking because their movement is affected by Functional Neurological Disorder (FND). The trial is testing a new treatment strategy that uses non-invasive brain stimulation to prepare the brain for specialist physical therapy. Participants will be randomly assigned to one of two groups. Both groups will complete three in-person sessions on three consecutive days. Participants in the treatment group have non-invasive brain stimulation, followed by specialist physical therapy. Participants in the comparison group have goal-setting and mental practice, followed by specialist physical therapy. Participants complete follow-up assessments by video call at 1 week, 1 month and 3 months after treatment, to evaluate their walking and balance. Participants are also asked to complete some simple online questionnaires at these follow-up time points. All assessments of walking and balance are carried out by a researcher who is unaware of which group the participant has been assigned to.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically established diagnosis of FND or an equivalent term
  • Investigations are accepted as complete by the patient and treating physician
  • Walking difficulty that prevents crossing the road unaided at a traffic light pedestrian crossing
  • Lower limb functional weakness
  • 30 days or more since first onset of functional motor symptoms
  • Tinetti POMA score < 21/28

Exclusion criteria

  • Age < 21 years
  • Living with a parent or guardian who provides primary emotional support and assistance with most daily tasks
  • Medical instability precluding safe participation in physical therapy
  • Cognitive or communication impairment precluding informed consent or the ability to effectively engage in education aspects of the trial with family support
  • Untreated and severe psychiatric illness affecting the ability to safely participate
  • Co-existing non-FND neurological or musculoskeletal impairments restricting walking independence
  • A primary diagnosis of chronic pain or chronic fatigue syndrome
  • Pain significantly limiting standing or walking
  • Prior treatment for FND that included Transcranial Magnetic Stimulation (TMS)
  • Contraindicated to TMS as determined using a standard safety screening checklist

Treatment and study plan

Stimulation-Enhanced Physical Therapy

Combination Product

The intervention uses Transcranial Magnetic Stimulation (TMS) to activate the motor pathways from the primary motor cortex to affected lower limb muscles. This is followed by specialist physical therapy applying consensus recommendations for the treatment of movement symptoms due to FND. Key elements include distraction, momentum, and exploratory movement.

Active comparator

Other

The active comparator uses structured goal-setting and movement imagery to prepare for physical therapy. This is followed by specialist physical therapy applying consensus recommendations for the treatment of movement symptoms due to FND. Key elements include distraction, momentum, and progressive movement retraining.

Primary outcomes

  1. Odds of achieving effective treatment defined as a Tinetti Performance-Oriented Mobility Assessment (POMA) score of at least 24 out of 28.

    Time frame: From enrolment until the Tinetti POMA score is evaluated immediately upon completion of treatment on day zero.

    The Tinetti POMA is a reliable and valid assessment for use with a broad range of neurological conditions, with excellent interrater reliability. It evaluates key symptom domains of gait, trunk stability, and postural balance. The minimum and worst score is zero. The maximum and best score is 28. The odds ratio for achieving effective treatment will be calculated for the treatment group relative to the control group.

Secondary outcomes

  1. Functional Movement Disorder Questionnaire (FMDQ)

    Time frame: Baseline, 30 days and 90 days post-treatment.

    The FMDQ is a summed severity and impact questionnaire in which participants rate the presence and severity of functional movement symptoms across multiple domains. Each item is scored on a Likert type scale, and a total score (range 31-181) is calculated, with higher scores indicating greater functional symptom burden.

  2. EQ-5D-5L

    Time frame: Baseline, 30 days post-treatment, and 90 days post-treatment.

    The EQ-5D-5L is a self-reported questionnaire of quality of life that is validated for general and neurological populations. The EQ-5D-5L assesses five key dimensions of health and using a 5-point Likert scale. An index score is derived from the combination of individual domain ratings using a country-specific value set which reflects societal preferences for different health states.

Other outcomes

  1. Tinetti POMA score during follow-up

    Time frame: 7 days, 30 days and 90 days post-treatment.

    The Tinetti POMA score will be obtained via video call during the follow-up period. It evaluates key symptom domains of gait, trunk stability, and postural balance. The minimum and worst score is zero. The maximum and best score is 28.

  2. Walking independence

    Time frame: Baseline, day -1 before treatment, day zero of treatment, and day 1 post-treatment, and at 7 days, 30 days and 90 days post-treatment.

    Walking independence will be evaluated with the Functional Ambulation Category (FAC), which is a valid and reliable measure of a person's level of independence in mobility and walking. The lowest and worst score is zero, meaning fully dependent. The highest and best score is 5, meaning fully independent walking. Participants will be classified as independent if they have a FAC score of 4 or 5 out of 5. Participants will be classified as dependent if they have a FAC score of 0, 1, 2 or 3.

  3. Simplified Functional Movement Disorders Rating Scale (S-FMDRS)

    Time frame: Day -1 before treatment, day zero of treatment, and day 1 post-treatment.

    The S-FMDRS is a clinician-rated score of overall functional movement symptom severity. The assessor will video the assessment to support their review and scoring accuracy. A total score out of 54 is recorded with higher scores indicating greater symptom severity.

  4. Lower limb strength

    Time frame: Day -1 before treatment, day zero of treatment, and day 1 post-treatment.

    Total lower limb strength score will be calculated by summing the Medical Research Council grades for knee flexion, knee extension, ankle dorsiflexion, and ankle plantarflexion for each limb. The summed bilateral score will be used for analysis of between-group effects. The minimum and worst score is zero, the maximum and best score is 40.

  5. Light touch sensation

    Time frame: Day -1 before treatment and day 1 post-treatment.

    Lower limb sensation will be assessed using Semmes-Weinstein monofilaments. With vision occluded, participants will be asked to indicate detection of progressively smaller filament sizes applied perpendicularly to the plantar surface of the great toe until the smallest reliably perceived filament is identified. Lower filament scores indicate better light touch sensation.

  6. Patient Global Impression of Improvement

    Time frame: Day zero after treatment and at 90 days post-treatment.

    The Patient Global Impression of Improvement (PGI-I) scale is a patient-reported measure used to evaluate participants' overall impression of change following treatment. The lowest score is zero, meaning "very much worse", and the highest score is 7, meaning "very much improved".

  7. Upper limb performance

    Time frame: Day -1 before treatment, day zero of treatment, and day 1 post-treatment.

    The Box and Blocks Test is a timed test of upper limb motor performance. It will be used to evaluate the more-affected upper limb of participants who report upper limb functional symptoms. More blocks moved in 60 seconds indicates better upper limb motor performance.

  8. Brief Illness Perception Questionnaire (B-IPQ)

    Time frame: Baseline and 90 days post-treatment.

    The Brief Illness Perception Questionnaire (B-IPQ) is a patient-reported measure of illness perception. Each of eight items is scored individually on a 0 to 10 scale. Higher scores indicate a more threatening or negative perception.

  9. Pain Interference

    Time frame: Baseline, and 7 days, 30 days and 90 days post-treatment.

    The PROMIS Pain Interference Short Form is a patient-reported measure of how much pain has interfered with daily activities over the past 7 days. The scale has 8 items, each rated on a 5-point scale with the lowest score of zero meaning "not at all", and the highest score of 5 meaning "very much".

  10. Fatigue Interference

    Time frame: Baseline, and 7 days, 30 days and 90 days post-treatment.

    The PROMIS Fatigue Interference Short Form is a patient-reported measure of how much pain has interfered with daily activities over the past 7 days. The scale has 8 items, each rated on a 5-point scale with the lowest score of zero meaning "not at all", and the highest score of 5 meaning "very much".

  11. Self-rated Function

    Time frame: Baseline and 90 days post-treatment.

    The Patient-Specific Functional Scale is an evaluation of participant-identified functional limitations. Participants nominate up to 3 activities they are currently unable to perform, or have difficulty performing, due to their symptoms. Each activity is rated on an 11-point scale from zero meaning 'unable to perform' to 10 meaning 'able to perform at prior level'.

  12. Treatment readiness

    Time frame: Day -1 before treatment and day zero of treatment.

    Treating clinicians will independently rate participant readiness to progress using a simple 4-point Likert scale, where zero means "definitely not ready" and 4 means "definitely ready".

  13. Employment status

    Time frame: Baseline and 90-days post-treatment.

    Participation in paid work or employment will be evaluated by asking participants to provide the average number of hours worked per week over the past 6 months. They will be asked to rate their perceived ability to work on a Likert scale, with a minimum score of zero meaning no ability to work, and a maximum score of 10 meaning able to fully participate in work.

Study contacts

Contact information is provided by the study sponsor or research team.

Cathy Stinear

CONTACT

[email protected]

+64210770788

Winston Byblow

CONTACT

[email protected]

+640211444252

Sponsors and collaborators

Lead sponsor

University of Auckland, New Zealand

Other

Registry information

Official study title

A Phase 3, Single-site, Assessor-blinded, Randomised Controlled Trial of Transcranial Magnetic Stimulation-Enhanced Treatment to Restore Movement Agency and Walking Independence in People With Functional Neurological Disorder

Acronym: RISE-FND

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Aug 18, 2026
Registry last updated
Aug 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.